Principles and practice of intraperitoneal chemotherapy for ovarian cancer

被引：68
作者：
Fujiwara, K.
Armstrong, D.
Morgan, M.
Markman, M.
机构：
[1] Saitama Med Univ, Dept Obstet & Gynecol, Moroyama, Saitama 3500495, Japan
[2] Johns Hopkins Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA
[3] Johns Hopkins Kimmel Canc Ctr, Dept Gynecol & Obstet, Baltimore, MD USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Med Oncol, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2007年 / 17卷 / 01期
关键词：
intraperitoneal chemotherapy; ovarian cancer;
D O I：
10.1111/j.1525-1438.2007.00809.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Intraperitoneal (IP) chemotherapy has been studied for years to improve the survival of patients with ovarian cancer. Recently, the result of Gynecologic Oncology Group 172 trial comparing IP versus intravenous administration of cisplatin-based chemotherapy was published, demonstrating the improvement of survival benefit in favor of the IP arm. This trial is the third trial that showed a survival benefit on IP chemotherapy. The National Cancer Institute (NCI) and Gynecologic Oncology Group have done a meta-analysis on the results of these three US trials and other phase III trials of IP versus intravenous chemotherapy, and significant improvement of survival was shown with IP therapy. Based on this meta-analysis, NCI has released a clinical announcement encouraging the gynecological oncology community to consider IP chemotherapy as the standard treatment for optimally debulked advanced ovarian cancer patients. However, there still are controversial issues regarding the use of IP chemotherapy. It is important to understand how IP chemotherapy works to solve those issues in the future. In this review article, we discuss the principles and clinical aspects of IP chemotherapy and also discuss the current problems and future perspectives in IP chemotherapy.
引用
收藏
页码：1 / 20
页数：20
相关论文
共 75 条
[1]  
Adachi S, 1994, Asia Oceania J Obstet Gynaecol, V20, P7
[2]  
ALBERTS DS, 1988, CANCER RES, V48, P5874
[3]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[4]  
[Anonymous], 2005, ANN ONCOL S8, V16, pviii7
[5]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[6]   A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment [J].
Barakat, RR ;
Almadrones, L ;
Venkatraman, ES ;
Aghajanian, C ;
Brown, C ;
Shapiro, F ;
Curtin, JP ;
Spriggs, D .
GYNECOLOGIC ONCOLOGY, 1998, 69 (01) :17-22
[7]   ESCALATING DOSE REGIMEN OF INTRAPERITONEAL MITOXANTRONE - PHASE-I STUDY - CLINICAL AND PHARMACOKINETIC EVALUATION [J].
BLOCHLDAUM, B ;
EICHLER, HG ;
RAINER, H ;
JAKESZ, R ;
SALZER, H ;
STEGER, G ;
SCHULLER, J ;
GUNTHER, E ;
PROKSCH, B ;
EHNINGER, G .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (07) :1133-1138
[8]   Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group [J].
Bookman, MA ;
McGuire, WP ;
Kilpatrick, D ;
Keenan, E ;
Hogan, WM ;
Johnson, SW ;
ODwyer, P ;
Rowinsky, E ;
Gallion, HH ;
Ozols, RF .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1895-1902
[9]   INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL [J].
BRALY, PS ;
BEREK, JS ;
BLESSING, JA ;
HOMESLEY, HD ;
AVERETTE, H .
GYNECOLOGIC ONCOLOGY, 1995, 56 (02) :164-168
[10]  
BURKART JM, 2004, KIDNEY, V2, P2625
12345678